Esophageal Squamous Cell Carcinoma

Further in vitro functional experiments confirmed that knockdown of TSHZ3 in ESCC cells significantly reduced NRG1 expression levels and inhibited the proliferative capacity of SCs in the co-culture system, providing more direct evidence for the TSHZ3-NRG1 regulatory axis. nmSCs infiltration predicts adverse prognosis in ESCC, and TSHZ3 may promote nmSCs infiltration via the NRG1 signaling axis.

The study found a positive correlation between Kla and ESCC metastasis. Furthermore, ENO1-Kla potentially promotes esophageal cancer (EC) metastasis and it may be a promising treatment target and a predictive biomarker of ESCC metastasis.

EZR is an oncogene that mediates the malignant progression of ESCC through two pathways: it impairs cell migration and invasion by attenuating focal adhesion activity, and inhibits cell proliferation by reducing EGFR activation-mediated PI3K-AKT signaling axis activation. These findings clarify the mechanism by which EZR contributes to ESCC progression and suggest a promising therapeutic target for ESCC treatment.

P2/3, N=90, Not yet recruiting, Peking University Cancer Hospital & Institute

Peroxisomes act as pivotal regulators of digestive cancer progression by modulating signaling pathways, the TIME, therapeutic resistance, and lipid metabolism. Targeting peroxisomal function, particularly in high-risk subgroups of HCC and CRC, warrants further exploration as a promising therapeutic strategy.

TIGIT, along with PD-L1 and CD163, is a potential prognostic marker for resectable ESCC. TIGIT is not only expressed in immune cells but also in ESCC tumor cells, suggesting its potential as a biomarker and therapeutic target. Further mechanistic studies are warranted to elucidate the downstream signaling pathways and validate the mechanisms of TIGIT in ESCC.

P=N/A, N=750, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2028

Given the aggressive nature of PSCCE and the limited evidence available to guide treatment, close surveillance following endoscopic resection of esophageal malignancies is essential, particularly in patients with underlying esophageal pathology. Further studies are needed to better define risk factors and optimal management strategies.

Pharmacogenomic analysis identified nine compounds (Shikonin, Bicalutamide, Bryostatin-1, Epothilone-B, JNK-9L, LFM-A13, QS11, VX-680, and Z-LLNle-CHO) exhibiting differential sensitivity between the dichotomous risk strata. This study yields findings that hold significant clinical implications for refining prognostic stratification and deciphering the immune landscape in ESCC. Moreover, they offer novel perspectives that may pave the way for more precise prognostic assessment and the formulation of targeted therapeutic interventions.

[This retracts the article DOI: 10.3389/fonc.2021.629916.].

Mechanistically, this integrated strategy combined tumor-targeted anchoring, immune-cell bridging, and innate immune activation within a single nanosystem. Together, these findings support the potential of this nanoplatform to remodel the ESCC immune microenvironment at the preclinical level and provide a basis for further investigation of macrophage-centered immunomodulatory strategies.

In conclusion, this study provides a comprehensive pan-cancer characterization of CHRNA7, offering novel insights into its potential role as a prognostic biomarker and immunotherapeutic target. These findings could facilitate the development of personalized cancer treatment strategies customized according to the expression level and functional status of CHRNA7.